Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice

American Journal of Gastroenterology

Volumn 104, Issue 7, 2009, Pages 1633-1641

  Lanas, Angel ^a,b,c   García Rodríguez, Luis A ^d   Polo Tomás, Mónica ^b   Ponce, Marta ^b,e   Alonso Abreu, Inmaculada ^f   Perez Aisa, Maria Angeles ^g   Perez Gisbert, Javier ^b,h   Bujanda, Luis ^b,i   Castro, Manuel ^j   Mũoz, Maria ^a   Rodrigo, Luis ^k   Calvet, Xavier ^b,l   Del Pino, Dolores ^a   Garcia, Santiago ^m  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^d Centro Espãol de Investigación Farmacoepidemiológica   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^g HOSPITAL COSTA DEL SOL   (Spain)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁱ HOSPITAL DONOSTIA   (Spain)

^j HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^k Hospital de Asturias   (Spain)

^l HOSPITAL DE SABADELL   (Spain)

^m HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

AGE DISTRIBUTION; ANALGESIA; ARTICLE; CASE FATALITY RATE; CLINICAL PRACTICE; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SPAIN; STATISTICAL ANALYSIS; UPPER GASTROINTESTINAL BLEEDING; VALIDATION STUDY;

EID: 85046588922     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.164     Document Type: Article

References (22)

1. Barkun A, Fallone CA, Chiba N, et al., Nonvariceal Upper GI Bleeding Consensus Conference Group. A Canadian clinical practice algorithm for the management of patients with nonvariceal upper gastrointestinal bleeding. Can J Gastroenterol 2004;18:605-9.
2. Pérez-Aisa MA, Del Pino D, Siles M et al. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther 2005;21:65-7.
3. Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer but not of its complications: a nation-wide study in the Netherland. Aliment Pharmacol Ther 2006;23:1587-93.
4. Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 2007;132:2320-7.
5. Sonnenberg A. Time trends of ulcer mortality in non-European countries. Am J Gastroenterol 2007;102:1101-7.
6. Kang JY, Elders A, Majeed A et al. Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982-2002. Aliment Pharmacol Ther 2006;24:65-79.
7. Lanas A, Perez-Aisa MA, Feu F, et al, Investigators of the Asociación Española de Gastroenterología (AEG). A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am 1 Gastroenterol 2005;100:1685-93.
8. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992;103:862-9.
9. Rahme E, Barkun A, Nedjar H et al. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol 2008;103:872-82.
10. Laine L, Connors LG, Reicin A et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003;124:288-92.
11. Laine L, Curtis SP, Langman M et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 2008;135:1517-25.
12. Ruiz U, Acedo K, Buenaventura R. et al. Implementing total quality management in the Spanish health care system. Qual Assur Health Care 1992;4:43-59.
13. Steven Harris. Medicare severity-refined DRGs: an improved system. www.irp.com.
14. Raiford DS, Pérez Gutthann S, García Rodríguez LA. Positive Predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology 1996;7:101-4.
15. Cattaruzzi C, Troncon MG, Agostinis L et al. Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database. J Clin Epidemiol 1999;52:499-502.
16. Lanas A, García-Rodríguez LA, Arroyo MT, et al, Asociación Española de Gastroenterología. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-8.
17. Goldstein JL, Eisen GM, Lewis B, et al., Investigators. Video capsule endos-copy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3:133-41.
18. Lanas A, Ballina J, Sobreviela E et al. Recent advances in the field of NSAID-associated side effects are not appropriately translated into clinical practice. Gastroenterology 2007;132 (Suppl2): A86.
19. Wilcox CM, Alexander LN, Cotsonis GA et al. Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci 1997;42:990-7.
20. Lanas A, García-Rodríguez LA, Arroyo MT, et al., Investigators of the Asociación Española de Gastroenterologí a (AEG). Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007;102:507-15.
21. Rostom A, Muir K, Dubé Cet al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration Systematic Review. Clin Gastroenterol Hepatol 2007;5:818-28.
22. Brown TJ, Hooper L, Elliott RA et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 2006;10: iii-iiv, xi-xiii, 1-183. 1707